MX2022013530A - Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador. - Google Patents

Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.

Info

Publication number
MX2022013530A
MX2022013530A MX2022013530A MX2022013530A MX2022013530A MX 2022013530 A MX2022013530 A MX 2022013530A MX 2022013530 A MX2022013530 A MX 2022013530A MX 2022013530 A MX2022013530 A MX 2022013530A MX 2022013530 A MX2022013530 A MX 2022013530A
Authority
MX
Mexico
Prior art keywords
bcma
cell therapy
combination
compositions
tautomer
Prior art date
Application number
MX2022013530A
Other languages
English (en)
Spanish (es)
Inventor
Michael Ports
Oleksandr Baturevych
Melissa Works
Neha Soni
John- Michael Williford
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2022013530A publication Critical patent/MX2022013530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022013530A 2020-04-28 2021-04-27 Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador. MX2022013530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063016983P 2020-04-28 2020-04-28
PCT/US2021/029503 WO2021222330A2 (en) 2020-04-28 2021-04-27 Combination of bcma-directed t cell therapy and an immunomodulatory compound

Publications (1)

Publication Number Publication Date
MX2022013530A true MX2022013530A (es) 2023-02-01

Family

ID=76502791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013530A MX2022013530A (es) 2020-04-28 2021-04-27 Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.

Country Status (11)

Country Link
US (1) US20230165872A1 (enExample)
EP (1) EP4142723A2 (enExample)
JP (1) JP2023524430A (enExample)
KR (1) KR20230015921A (enExample)
CN (1) CN116157125A (enExample)
AU (1) AU2021263765A1 (enExample)
BR (1) BR112022021788A2 (enExample)
CA (1) CA3181399A1 (enExample)
IL (1) IL297688A (enExample)
MX (1) MX2022013530A (enExample)
WO (1) WO2021222330A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN118201618A (zh) * 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
CA3233953A1 (en) * 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025137751A1 (pt) * 2023-12-26 2025-07-03 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7204296B2 (en) 2004-07-26 2007-04-17 Metal Casting Technology, Incorporated Method of removing a fugitive pattern from a mold
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
PL3198345T3 (pl) 2014-09-22 2021-08-23 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linia do produkcji pojedynczych wyrobów w następujących po sobie w cyklu ciągłym
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
WO2018085690A1 (en) * 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
SG11202000606TA (en) 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
PT3703750T (pt) * 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
MA54078A (fr) * 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CA3117978A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN113747896A (zh) * 2019-04-22 2021-12-03 斯塔顿治疗公司 来那度胺和其他免疫调节剂的连续递送
IL292667B1 (en) * 2019-11-07 2026-02-01 Juno Therapeutics Inc Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione

Also Published As

Publication number Publication date
KR20230015921A (ko) 2023-01-31
CN116157125A (zh) 2023-05-23
IL297688A (en) 2022-12-01
CA3181399A1 (en) 2021-11-04
AU2021263765A1 (en) 2022-12-01
JP2023524430A (ja) 2023-06-12
EP4142723A2 (en) 2023-03-08
WO2021222330A3 (en) 2021-12-09
WO2021222330A2 (en) 2021-11-04
BR112022021788A2 (pt) 2023-01-17
US20230165872A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2022013530A (es) Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.
PH12021552922A1 (en) Solid state forms
RU2437882C2 (ru) Производные имидазолидинона
IL178747A (en) 3 - (4-amino-1-oxo-1, 3-dihydro-isoindole-2-yl) -pipridine-6,2-discussion or acceptable pharmaceutical salt, solvate or steroid isomer for use in the treatment of non-Hodgkin's lymphoma, also optional Combined with other therapeutic factors
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
US20160311833A1 (en) Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
MX2019003726A (es) Metodos para tratar fibroides uterinos y endometriosis.
JP2023545274A (ja) 癌を処置する化合物および方法
EP4302761A3 (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
JP2017525757A5 (enExample)
JP2020503299A5 (enExample)
RU2013124824A (ru) Твердые дисперсии, содержащие средства, вызывающие апоптоз
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
MX2008008405A (es) Metodos para tratar lupus cutaneo usando compuestos de aminoisoindolina.
RU2004132203A (ru) Индолилмалеимидные производные
TW201617337A (zh) 經苯甲基取代之吲唑
JP6761413B2 (ja) シグマ受容体結合剤
CN106414435A (zh) 氨基‑取代的异噻唑
MY210324A (en) 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
MX2024011914A (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
WO2006135713A2 (en) Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor
RU2007102274A (ru) Пиперазиндионы как антагонисты рецептора окситоцина
JP2009537606A5 (enExample)